Vor Biopharma Inc.

Vor Biopharma Inc.

VOR·NASDAQ

$13.44

-0.037%
HealthcareBiotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$92.12M
EPS-70.5000
P/E Ratio-0.19
Earnings Date08/11/2026

vor

Net Common Stock Issuance

Last Annual Value

505.13M

3-Year CAGR

63%

5-Year CAGR

%

10-Year CAGR

%

Vor Biopharma Inc.

Vor Biopharma Inc. Competitors Analysis of Net Common Stock Issuance

VOR · NASDAQ
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
505.13M
379.6%21.7%N/A 
76.83M
45.9%315.6%144.7%
0.00
N/AN/AN/A
CDXS logo
Codexis, Inc.
NASDAQ:CDXS
18.03M
27.7%29.4%N/A
8.25M
-51.9%-27.4%-23.7%
77.43M
1031.8%4.3%16.6%
9.89M
-37.0%133.4%N/A
19.32M
-13.4%22.3%N/A
OABI logo
OmniAb, Inc.
NASDAQ:OABI
28.36M
N/AN/AN/A
71.97M
556.8%N/AN/A
82.90M
N/AN/A82.0%
Vor Biopharma Inc.

Vor Biopharma Inc. Fair Value Envelope

VOR · NASDAQ

Our analysis suggests that VOR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $13.44, this represents a potential HIDDEN relative to our calculated worth for Vor Biopharma Inc..

Intrinsic Value
Current Price: $13.44